WT1表达对急性白血病异基因造血干细胞移植预后的影响
回顾性分析2016年1月至2017年12月在浙江大学医学院附属第一医院骨髓移植中心行异基因造血干细胞移植的314例急性白血病患者,比较初诊时、移植前、移植后WT1表达,通过ROC曲线确定预测复发的临界值。移植前及移植后WT1高表达是影响预后的不利因素,WT1作为移植推荐指标和移植后MRD监测手段存在临床实用价值。
要点
- 移植前WT1高表达组OS、DFS低于低表达组,CIR高于低表达组。
- 移植后6个月WT1>0.375%是影响DFS的独立危险因素(P=0.022)。
- 移植后3个月WT1高表达组与低表达组OS、DFS差异无统计学意义。
核心结论
- 移植前及移植后WT1高表达是影响预后的不利因素。
- 将WT1作为急性白血病患者造血干细胞移植的推荐指标和移植后MRD的监测手段存在临床实用价值。
研究设计与样本
- 回顾性分析2016年1月至2017年12月在浙江大学医学院附属第一医院骨髓移植中心行异基因造血干细胞移植的314例急性白血病患者,男163例,女151例,中位年龄30(9~64)岁。
主要发现
- 移植前WT1高表达组OS低于低表达组[69.2%(9/13)对89.1%(57/64),χ²=4.086,P=0.043]。
- 移植前WT1高表达组DFS低于低表达组[53.8%(7/13)对87.5%(56/64),χ²=9.766,P=0.002]。
- 移植前WT1高表达组CIR高于低表达组[30.8%(4/13)对7.8%(5/64),P=0.017]。
- 移植后3个月WT1高表达组与低表达组OS、DFS差异均无统计学意义(P=0.558,P=0.269)。
- 移植后6个月WT1高表达组OS、DFS均低于低表达组(P=0.049,P=0.035);移植后3个月及6个月高表达组与低表达组CIR差异无统计学意义(P=0.114,P=0.306)。
关键数值与推荐
- 移植前WT1表达量预测复发的临界值为1.010%。
- 移植后3个月内WT1表达量预测复发的临界值为0.079%。
- 移植后6个月WT1表达量预测复发的临界值为0.375%。
- 多因素分析显示移植后6个月WT1表达>0.375%是影响DFS的独立危险因素(P=0.022)。
临床怎么用
- 作者认为将WT1作为急性白血病患者造血干细胞移植的推荐指标和移植后MRD的监测手段存在临床实用价值。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To study the effect of WT1 expression on the prognosis of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute leukemia (AL) and its significance as molecular marker to dynamically monitor minimal residual disease (MRD) . Methods: Retrospectively analyzed those AL patients who underwent allo-HSCT in the First Hospital Affiliated to Zhejiang University School of Medicine during Jan 2016 to Dec 2017, a total number of 314 cases, 163 males and 151 females, median age was 30 (9-64) years old. Comparing the difference of WT1 expression at diagnosed, pre-HSCT and after HSCT. Using the receiver operating characteristic (ROC) curve to determine the WT1 threshold at different time so as to predict relapse. The threshold of WT1 expression before transplantation was 1.010%, within 3 months after HSCT was 0.079% and 6 months after HSCT was 0.375%. According to these thresholds, WT1 positive patients were divided into low expression groups and high expression groups. Analyzed the relationship between overall survival (OS) , disease-free survival (DFS) , cumulative incidence of relapse (CIR) and WT1 expression. Results: The OS and DFS of high expression group pre-HSCT were lower than low expression group [69.2% (9/13) vs 89.1% (57/64) , χ(2)=4.086, P=0.043; 53.8% (7/13) vs 87.5% (56/64) , χ(2)=9.766, P=0.002], CIR was higher than low expression group [30.8% (4/13) vs 7.8% (5/64) , P=0.017]. There was no significant difference of OS and DFS between high expression and low expression group of 3 months after HSCT (P=0.558, P=0.269) . The OS and DFS of high expression group of 6 months after transplantation were both lower than low expression group (P=0.049, P=0.035) . Multivariate analysis showed that WT1>0.375% when 6 months after transplantation was the only independent prognostic factor for shorter DFS (P=0.022) . There was no statistically significant difference in CIR between the high-expression group and the low-expression group 3 months after transplantation and 6 months after transplantation (P=0.114, P=0.306) . Conclusion: High expression of WT1 before and after HSCT was an adverse prognosis factor. It is of clinical practical value to use WT1 as a transplant recommendation index for patients with acute leukemia and as a marker to monitor MRD dynamically. 目的: 研究WT1表达水平对急性白血病异基因造血干细胞移植预后的影响及其作为分子学标志来动态监测微小残留病(MRD)的意义。 方法: 回顾性分析2016年1月至2017年12月在浙江大学医学院附属第一医院骨髓移植中心行异基因造血干细胞移植的314例急性白血病患者,男163例,女151例,中位年龄30(9~64)岁,比较初诊时、移植前、移植后WT1表达,通过ROC曲线确定移植前、移植后3个月内及移植后6个月WT1表达量预测复发的临界值分别为1.010%、0.079%、0.375%,根据上述临界值将WT1阳性患者分为低表达组和高表达组,分析移植后总生存(OS)、无病生存(DFS)以及累积复发率(CIR)与WT1表达量之间的关系。 结果: 移植前WT1高表达组的OS、DFS率均低于低表达组[69.2%(9/13)对89.1%(57/64),χ(2)=4.086,P=0.043;53.8%(7/13)对87.5%(56/64),χ(2)=9.766,P=0.002],CIR高于低表达组[30.8%(4/13)对7.8%(5/64),P=0.017]。移植后3个月WT1高表达组、低表达组OS、DFS率差异均无统计学意义(P=0.558,P=0.269)。移植后6个月WT1高表达组OS、DFS率均低于低表达组(P=0.049,P=0.035)。多因素分析显示,移植后6个月WT1表达>0.375%是影响DFS的独立危险因素(P=0.022),移植后3个月内及移植后6个月WT1高表达组的复发率与低表达组比较差异无统计学意义(P=0.114,P=0.306)。 结论: 移植前及移植后WT1高表达是影响预后的不利因素,将WT1作为急性白血病患者造血干细胞移植的推荐指标和移植后MRD的监测手段存在临床实用价值。.
引用
- Jiang BQ, Luo Y, Zhao YM, et al. [The effect of WT1 expression on the prognosis of allogeneic hematopoietic stem cell transplantation in acute leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 30612399. doi:10.3760/cma.j.issn.0253-2727.2018.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。